Skip to main content
. Author manuscript; available in PMC: 2020 Aug 31.
Published in final edited form as: Invest New Drugs. 2016 Jul 21;34(6):733–739. doi: 10.1007/s10637-016-0376-1

Figure 1:

Figure 1:

Time to and Reason(s) for Discontinuation of Therapy.

*Denotes a patient who had a partial response to treatment

PD: Progressive disease; AE: Adverse Event; DLT: Dose Limiting Toxicity